SelectQuote Q3 Earnings Beat Expectations Despite Revenue Miss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy SLQT?
Source: seekingalpha
SelectQuote's stock surged by nearly 50% as it crossed above the 5-day SMA, reflecting strong investor interest following its Q3 earnings report.
The company reported a Q3 GAAP EPS of $0.11, exceeding expectations by $0.10, which indicates stable profitability and could enhance investor confidence. However, revenue of $430.9 million fell short of expectations by $8.03 million, highlighting challenges from increased market competition and rising customer acquisition costs. Despite these challenges, SelectQuote's net income of $40.2 million and adjusted EBITDA of $44.6 million demonstrate operational efficiency, and the company projects FY 2026 revenue between $1.61 billion and $1.71 billion, reflecting a cautiously optimistic outlook.
The strong earnings beat, despite the revenue miss, suggests that SelectQuote is managing its costs effectively, which may attract more investors looking for stability in a competitive market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLQT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLQT
Wall Street analysts forecast SLQT stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.140
Low
5.00
Averages
6.00
High
7.00
Current: 1.140
Low
5.00
Averages
6.00
High
7.00
About SLQT
SelectQuote, Inc. provides a technology-enabled, direct-to-consumer (DTC) distribution and engagement platform for selling insurance policies and healthcare services. The Company has four core business lines: SelectQuote Senior, SelectQuote Healthcare Services, SelectQuote Life, and SelectQuote Auto and Home. SelectQuote’s Senior division sells Medicare Advantage, Medicare Supplement, Medicare Part D, and other ancillary senior health insurance related products. SelectQuote Healthcare Services comprises SelectRx Pharmacy, a specialized medication management pharmacy, and Population Health which proactively connects its members with healthcare services that fit each member's healthcare needs. SelectQuote’s Auto & Home division primarily sells non-commercial auto and home, property and casualty insurance products. SelectQuote’s Life division sells term life, final expenses, and other ancillary products. SelectRx is a Patient-Centered Pharmacy Home (PCPH) accredited pharmacy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SelectQuote Reports Strong Q3 2026 Earnings with Positive Outlook
- Strong Financial Performance: SelectQuote generated $431 million in revenue for Q3 2026, reflecting a 6% year-over-year increase, with adjusted EBITDA reaching $45 million, indicating robust growth across all business segments and boosting market confidence.
- Senior Business Growth: Revenue from the Senior segment grew 8% year-over-year to $183 million, demonstrating the company's successful optimization of commission receivables amid improved approval rates for Medicare Advantage policies, with an anticipated asset benefit of approximately $1 billion in the future.
- SelectRx Challenges and Opportunities: Despite facing headwinds from carrier-specific reimbursement policies and the Inflation Reduction Act, SelectRx's adjusted EBITDA improved sequentially to $5 million, showcasing the company's resilience in seeking profitability in challenging conditions.
- Optimistic Future Outlook: The company reaffirmed its revenue guidance for fiscal 2026 in the range of $1.61 billion to $1.71 billion and adjusted EBITDA guidance between $90 million and $100 million, with management expressing increased confidence in accelerating cash flow, which is expected to drive growth in fiscal 2027.
See More
SelectQuote Q3 Earnings Beat Expectations Despite Revenue Miss
- Earnings Beat: SelectQuote reported a Q3 GAAP EPS of $0.11, exceeding expectations by $0.10, indicating stable profitability that could enhance investor confidence in the company's financial performance.
- Revenue Miss: Despite a year-over-year revenue increase of 5.6% to $430.9 million, the figure fell short of expectations by $8.03 million, highlighting challenges from increased market competition and rising customer acquisition costs that may impact future growth potential.
- Net Income and Adjusted EBITDA: The company achieved a net income of $40.2 million and an adjusted EBITDA of $44.6 million, demonstrating some success in cost control and operational efficiency, which strengthens its overall financial health.
- Fiscal Year 2026 Guidance: SelectQuote projects revenue for FY 2026 to range between $1.61 billion and $1.71 billion, with adjusted EBITDA expected between $90 million and $100 million, reflecting a cautiously optimistic outlook for future growth despite external challenges.
See More
SelectQuote Scheduled to Announce Q3 Earnings on May 5
- Earnings Announcement: SelectQuote (SLQT) is set to release its Q3 earnings results on May 5 before market open, with consensus EPS estimated at $0.01 and revenue projected at $438.93 million, reflecting a 33.5% year-over-year growth.
- Performance Expectations: Over the past year, SelectQuote has exceeded EPS estimates 75% of the time and has beaten revenue estimates 100% of the time, indicating a strong track record of financial performance.
- Revision Trends: In the last three months, there have been no upward revisions to EPS estimates and one downward revision, while revenue estimates have seen four downward adjustments, suggesting market caution regarding the company's future outlook.
- Market Challenges: SelectQuote recently received a notice from the NYSE for having a share price below $1 and has lowered its 2026 guidance amid a $40 million headwind, yet it aims for a senior EBITDA margin of over 20% and operating cash flow between $25 million and $35 million.
See More
SelectQuote to Release Q3 2026 Financial Results on May 5
- Earnings Release Schedule: SelectQuote will announce its fiscal Q3 2026 financial results before market open on May 5, 2026, which is expected to significantly impact investor sentiment.
- Executive Conference Call: CEO Tim Danker and CFO Ryan Clement will host a conference call at 8:30 AM ET on the release day to discuss the financial results, enhancing transparency and investor confidence.
- Company Background: Founded in 1985, SelectQuote pioneered the model of providing unbiased comparisons from multiple highly-rated insurance companies, allowing consumers to choose policies that best meet their needs, showcasing its leadership in the insurance sector.
- Business Ecosystem: The company operates three core business lines, including SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life, aimed at addressing the growing Medicare needs of approximately 10,000 seniors turning 65 daily, supporting the healthcare insurance demands of 65 million elderly consumers.
See More
SelectQuote Executives Allegedly Breached Fiduciary Duties
- Legal Investigation Initiated: Kuehn Law, PLLC is investigating whether executives at SelectQuote, Inc. breached their fiduciary duties to shareholders, with allegations that could lead to significant legal repercussions for the company.
- False Statements Exposed: According to a federal securities lawsuit, SelectQuote is accused of failing to disclose that its recommendations to Medicare beneficiaries were primarily based on compensation to the company rather than the quality or suitability of the insurance plans.
- Improper Conduct Allegations: SelectQuote is alleged to have failed to provide unbiased comparisons of Medicare Advantage plans and received illegal kickbacks to steer beneficiaries to specific insurers, potentially violating the False Claims Act.
- Increased Compliance Risks: As a result of these actions, SelectQuote may face regulatory and legal sanctions, leading to previous positive statements about the company being deemed misleading and lacking a reasonable basis.
See More
SelectQuote Executives Allegedly Breached Fiduciary Duties
- Legal Investigation Launched: Kuehn Law, PLLC is investigating whether executives at SelectQuote, Inc. breached their fiduciary duties to shareholders, with allegations that the company misled investors by failing to disclose its practices regarding Medicare beneficiaries, potentially harming shareholder interests.
- Misconduct Allegations: The lawsuit claims that SelectQuote directed Medicare beneficiaries to insurers that compensated the company best, rather than providing unbiased comparisons, exposing the firm to legal and regulatory sanctions.
- Potential Legal Consequences: SelectQuote's actions may have violated the False Claims Act, leading to risks of regulatory and legal penalties that could adversely affect the company's future operations and reputation.
- Shareholder Rights Protection: Kuehn Law urges shareholders to contact attorneys promptly to protect their rights, emphasizing that shareholder voices are crucial for the integrity and fairness of financial markets.
See More
SelectQuote Reports Strong Q3 2026 Earnings with Positive Outlook
- Strong Financial Performance: SelectQuote generated $431 million in revenue for Q3 2026, reflecting a 6% year-over-year increase, with adjusted EBITDA reaching $45 million, indicating robust growth across all business segments and boosting market confidence.
- Senior Business Growth: Revenue from the Senior segment grew 8% year-over-year to $183 million, demonstrating the company's successful optimization of commission receivables amid improved approval rates for Medicare Advantage policies, with an anticipated asset benefit of approximately $1 billion in the future.
- SelectRx Challenges and Opportunities: Despite facing headwinds from carrier-specific reimbursement policies and the Inflation Reduction Act, SelectRx's adjusted EBITDA improved sequentially to $5 million, showcasing the company's resilience in seeking profitability in challenging conditions.
- Optimistic Future Outlook: The company reaffirmed its revenue guidance for fiscal 2026 in the range of $1.61 billion to $1.71 billion and adjusted EBITDA guidance between $90 million and $100 million, with management expressing increased confidence in accelerating cash flow, which is expected to drive growth in fiscal 2027.
See More
SelectQuote Q3 Earnings Beat Expectations Despite Revenue Miss
- Earnings Beat: SelectQuote reported a Q3 GAAP EPS of $0.11, exceeding expectations by $0.10, indicating stable profitability that could enhance investor confidence in the company's financial performance.
- Revenue Miss: Despite a year-over-year revenue increase of 5.6% to $430.9 million, the figure fell short of expectations by $8.03 million, highlighting challenges from increased market competition and rising customer acquisition costs that may impact future growth potential.
- Net Income and Adjusted EBITDA: The company achieved a net income of $40.2 million and an adjusted EBITDA of $44.6 million, demonstrating some success in cost control and operational efficiency, which strengthens its overall financial health.
- Fiscal Year 2026 Guidance: SelectQuote projects revenue for FY 2026 to range between $1.61 billion and $1.71 billion, with adjusted EBITDA expected between $90 million and $100 million, reflecting a cautiously optimistic outlook for future growth despite external challenges.
See More
SelectQuote Scheduled to Announce Q3 Earnings on May 5
- Earnings Announcement: SelectQuote (SLQT) is set to release its Q3 earnings results on May 5 before market open, with consensus EPS estimated at $0.01 and revenue projected at $438.93 million, reflecting a 33.5% year-over-year growth.
- Performance Expectations: Over the past year, SelectQuote has exceeded EPS estimates 75% of the time and has beaten revenue estimates 100% of the time, indicating a strong track record of financial performance.
- Revision Trends: In the last three months, there have been no upward revisions to EPS estimates and one downward revision, while revenue estimates have seen four downward adjustments, suggesting market caution regarding the company's future outlook.
- Market Challenges: SelectQuote recently received a notice from the NYSE for having a share price below $1 and has lowered its 2026 guidance amid a $40 million headwind, yet it aims for a senior EBITDA margin of over 20% and operating cash flow between $25 million and $35 million.
See More
SelectQuote to Release Q3 2026 Financial Results on May 5
- Earnings Release Schedule: SelectQuote will announce its fiscal Q3 2026 financial results before market open on May 5, 2026, which is expected to significantly impact investor sentiment.
- Executive Conference Call: CEO Tim Danker and CFO Ryan Clement will host a conference call at 8:30 AM ET on the release day to discuss the financial results, enhancing transparency and investor confidence.
- Company Background: Founded in 1985, SelectQuote pioneered the model of providing unbiased comparisons from multiple highly-rated insurance companies, allowing consumers to choose policies that best meet their needs, showcasing its leadership in the insurance sector.
- Business Ecosystem: The company operates three core business lines, including SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life, aimed at addressing the growing Medicare needs of approximately 10,000 seniors turning 65 daily, supporting the healthcare insurance demands of 65 million elderly consumers.
See More
SelectQuote Executives Allegedly Breached Fiduciary Duties
- Legal Investigation Initiated: Kuehn Law, PLLC is investigating whether executives at SelectQuote, Inc. breached their fiduciary duties to shareholders, with allegations that could lead to significant legal repercussions for the company.
- False Statements Exposed: According to a federal securities lawsuit, SelectQuote is accused of failing to disclose that its recommendations to Medicare beneficiaries were primarily based on compensation to the company rather than the quality or suitability of the insurance plans.
- Improper Conduct Allegations: SelectQuote is alleged to have failed to provide unbiased comparisons of Medicare Advantage plans and received illegal kickbacks to steer beneficiaries to specific insurers, potentially violating the False Claims Act.
- Increased Compliance Risks: As a result of these actions, SelectQuote may face regulatory and legal sanctions, leading to previous positive statements about the company being deemed misleading and lacking a reasonable basis.
See More
SelectQuote Executives Allegedly Breached Fiduciary Duties
- Legal Investigation Launched: Kuehn Law, PLLC is investigating whether executives at SelectQuote, Inc. breached their fiduciary duties to shareholders, with allegations that the company misled investors by failing to disclose its practices regarding Medicare beneficiaries, potentially harming shareholder interests.
- Misconduct Allegations: The lawsuit claims that SelectQuote directed Medicare beneficiaries to insurers that compensated the company best, rather than providing unbiased comparisons, exposing the firm to legal and regulatory sanctions.
- Potential Legal Consequences: SelectQuote's actions may have violated the False Claims Act, leading to risks of regulatory and legal penalties that could adversely affect the company's future operations and reputation.
- Shareholder Rights Protection: Kuehn Law urges shareholders to contact attorneys promptly to protect their rights, emphasizing that shareholder voices are crucial for the integrity and fairness of financial markets.
See More
